Text Size
45 studies found for:    Empagliflozin

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Does the Intake of Food Influence the Uptake of Empagliflozin (BI 10773) ? Does the Amount of Empagliflozin (BI 10773), That is Taken up Into the Body After Intake of 10 mg and 25 mg Tablets, Increase Proportional With the Dose ?
Condition: Healthy
Intervention: Drug: Empagliflozin
2 Completed Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers
Condition: Healthy
Interventions: Drug: BI 10773 25 mg;   Drug: Warfarin 25 mg;   Drug: Warfarin
3 Completed Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
Condition: Healthy
Interventions: Drug: BI 10773/linagliptin;   Drug: BI 10773/linagliptin SID;   Drug: BI 10773/linagliptin FDC
4 Completed Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers
Condition: Healthy
Interventions: Drug: BI 10773;   Drug: Gemfibrozil
5 Active, not recruiting Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: Placebo;   Drug: Sitagliptin 100mg
6 Recruiting Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: BI 10773 Placebo;   Drug: BI 10773 / BI 1356;   Drug: BI 10773 / BI 1356 Placebo
7 Recruiting Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2;   Hyperglycemia
Interventions: Drug: Empagliflozin low dose qd;   Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin high dose qd;   Drug: Empagliflozin low dose bid;   Drug: Empagliflozin high dose bid
8 Completed Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
Condition: Healthy
Interventions: Drug: BI 10773;   Drug: Ramipril
9 Recruiting A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: empagliflozin (low dose qd);   Drug: Empagliflozin (high dose qd);   Drug: empagliflozin (high dose bid);   Drug: empagliflozin (low dose bid)
10 Completed Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo (low dose);   Drug: Placebo (mid dose);   Drug: Placebo (high dose);   Drug: BI 10773
11 Recruiting Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
Condition: Healthy
Interventions: Drug: Empagliflozin;   Drug: Metformin;   Drug: Empagliflozin/Metformin
12 Completed Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: BI10773
13 Active, not recruiting Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: BI 10773 high dose;   Drug: high dose FDC placebo;   Drug: linagliptin;   Drug: low dose FDC placebo;   Drug: BI 10773 linagliptin FDC;   Drug: high dose BI 10773 placebo;   Drug: BI 10773 low dose;   Drug: linagliptin placebo;   Drug: low dose BI 10773 placebo
14 Completed Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: C: BI 10773 / metformin tablet;   Drug: B: BI 10773 tablet and metformin tablet;   Drug: A: BI 10773 / metformin tablet
15 Completed Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo identical to BI10773 high dose;   Drug: BI 10773;   Drug: BI 10773 open label;   Drug: Placebo identical to BI10773 low dose;   Drug: Placebo identical to Sitagliptin 100mg;   Drug: BI10773;   Drug: Sitagliptin
16 Completed Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo identical to BI 10773 high dose;   Drug: Placebo identical to BI 10773 low dose;   Drug: BI 10773
17 Completed 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo (middle dose);   Drug: Placebo;   Drug: BI 10773;   Drug: Placebo (high dose);   Drug: Placebo (low dose)
18 Completed 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
Conditions: Diabetes Mellitus, Type 2;   Hypertension
Interventions: Drug: Placebo;   Drug: BI 10773
19 Recruiting Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets
Condition: Healthy
Interventions: Drug: empagliflozin;   Drug: metformin (Glucophage®);   Drug: empagliflozin and metformin
20 Completed Pharmacokinetics and Pharmacodynamics of Empagliflozin( BI 10773 )
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI10773;   Drug: Placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years